Reply To: Traders Market Weekly: Embrace the Chaos in 2023

#49680
TradersCom
Keymaster

Gilead Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study

Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
– 35-45% Reduction in Risk of Progression or Death and a Doubling of mPFS Were Observed in the Domvanalimab-Containing Study Arms, Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC –

– With Median Follow-Up of Approximately 12 Months, Both Domvanalimab-Containing Study Arms Also Improved ORR and Six-Month Landmark PFS Compared to Zimberelimab Monotherapy –

– Detailed Results Will Be Presented on December 20at 3pm ET / 12pm PT during the ASCO Monthly Plenary Series –

https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/anti-tigit-domvanalimab-containing-study-arms-improve-progression-free-survival-compared-to-anti-pd1-alone-in-phase-2-non-small-cell-lung-cancer-study